A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma

Journal of Dermatological Treatment

Volumn 19, Issue 2, 2008, Pages 111-117

  Ezughah, Francesca I ^a   Dawe, Robert S ^a   Ibbotson, Sally H ^a   Fleming, Colin J ^a  

^a NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

Basal cell cancer; Cycled dosing regimens; Imiquimod; Randomized parallel study; Superficial basal cell carcinoma

Indexed keywords

ANTIBIOTIC AGENT; IMIQUIMOD;

ADULT; AGED; APPLICATION SITE PAIN; APPLICATION SITE SCABBING; APPLICATION SITE SWELLING; APPLICATION SITE WEEPING; ARTICLE; BACTERIAL INFECTION; BASAL CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

ADULT; AGED; AGED, 80 AND OVER; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 45949106337     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630701557965     Document Type: Article

References (10)

1. Wong CSM, Strange RC, Lear JT. Basal cell carcinoma. Br Med J. 2003;327:794-8.
2. Marks R, Gebauer K, Shumack S, Amies M, Bryden J, Fox TL, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicenter 6-week dose-response trial. J Am Acad Dermatol. 2001;44:807-13.
3. Schulze HJ, Cribier B, Requena L, Reifenberger J, Ferrandiz C, Diez AG, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005;152:939-47.
4. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50:722-33.
5. Vidal D, Matias-Guiu X, Alomar A. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma. Clin Exp Dermatol. 2004;29:518-25.
6. Stockfleth E, Trefzer U, Garcia-Bartels C, Wegner T, Schmook T, Sterry W. The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: An overview. Br J Dermatol. 2003;149:53-6.
7. Testerman TL, Gerster JF, Imbertson LM, Reiter MJ, Miller RL, Gibson SJ, et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol. 1995;58:365-72.
8. Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol. 1999;41:1002-7.
9. Sterry W, Ruzicka T, Herrera E, Takwale A, Bichel J, Andres K, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: Randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol. 2002;147:1227-36.
10. Gollnick H, Barona CG, Frank RGJ, Ruzicka T, Megahed M, Tebbs V, et al. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: Interim 2-year results from an ongoing 5-year follow-up study in Europe. Eur J Dermatol. 2005;15:374-81.